Seth Klarman: portfolio of Baupost Group
Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.
Source: 13F filing with the US Securities and Exchange Commission dated Nov 14, 2016. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
You are looking at Q3 2016. Go to the latest filing (Q3 2026)
- Total value of stock positions
- 7.0B USD
- Positions
- 43
- Share of the ten largest
- 69.7%
The ten largest positions Q3 2016
- Cheniere Energy Inc 17.4%▼ −6.7%
- Viasat Inc 12.3%unchanged
- Synchrony Financial 7.0%new
- Allergan PLC 6.6%unchanged
- Antero Res Corp 5.6%unchanged
- Pbf Energy Inc 5.1%▲ +47.8%
- Dell Technologies 4.5%new
- Twenty First Centy Fox Inc 4.4%▲ +65.6%
- Theravance Biopharma Inc 3.8%unchanged
- PayPal 2.9%▼ −11.7%
Show all positions of this quarter
Choose a quarter (54 filings)
- Q3 2026
- Q2 2026
- Q1 2026
- Q4 2025
- Q3 2025
- Q2 2025
- Q1 2025
- Q4 2024
- Q3 2024
- Q2 2024
- Q1 2024
- Q4 2023
- Q3 2023
- Q2 2023
- Q1 2023
- Q4 2022
- Q3 2022
- Q2 2022
- Q1 2022
- Q4 2021
- Q3 2021
- Q2 2021
- Q1 2021
- Q4 2020
- Q3 2020
- Q2 2020
- Q1 2020
- Q4 2019
- Q3 2019
- Q2 2019
- Q1 2019
- Q4 2018
- Q3 2018
- Q2 2018
- Q1 2018
- Q4 2017
- Q3 2017
- Q2 2017
- Q1 2017
- Q4 2016
- Q3 2016
- Q2 2016
- Q1 2016
- Q4 2015
- Q3 2015
- Q2 2015
- Q1 2015
- Q4 2014
- Q3 2014
- Q2 2014
- Q1 2014
- Q4 2013
- Q3 2013
- Q2 2013
All positions Q3 2016
| Symbol | Weight | Shares | Reported value | Change | Held since |
|---|---|---|---|---|---|
| Cheniere Energy Inc | 17.4% | 27,842,957 | 1.2B USD | −6.7% reduced | Q1 2014 11 quarters |
| Viasat Inc | 12.3% | 11,533,137 | 860.9M USD | unchanged | Q2 2013 or earlier 14 quarters |
| SYF Synchrony Financial | 7.0% | 17,565,000 | 491.8M USD | new | Q3 2016 1 quarter |
| Allergan PLC | 6.6% | 2,001,978 | 461.1M USD | unchanged | Q1 2016 3 quarters |
| Antero Res Corp | 5.6% | 14,505,881 | 390.9M USD | unchanged | Q3 2014 9 quarters |
| Pbf Energy Inc | 5.1% | 15,724,175 | 356.0M USD | +47.8% increased | Q3 2013 13 quarters |
| DELL Dell Technologies | 4.5% | 6,652,459 | 318.0M USD | new | Q3 2016 1 quarter |
| Twenty First Centy Fox Inc | 4.4% | 12,746,469 | 308.7M USD | +65.6% increased | Q3 2015 5 quarters |
| Theravance Biopharma Inc | 3.8% | 7,350,991 | 266.4M USD | unchanged | Q2 2014 10 quarters |
| PYPL PayPal | 2.9% | 5,000,000 | 204.9M USD | −11.7% reduced | Q3 2015 5 quarters |
| Twenty First Centy Fox Inc | 2.6% | 7,278,100 | 180.1M USD | unchanged | Q3 2015 5 quarters |
| Innoviva Inc | 2.3% | 14,931,483 | 164.1M USD | −15.2% reduced | Q1 2016 3 quarters |
| Veritiv Corp | 2.2% | 3,044,385 | 152.7M USD | unchanged | Q3 2014 9 quarters |
| Keryx Biopharmaceuticals Inc | 2.0% | 25,791,678 | 137.0M USD | unchanged | Q1 2014 11 quarters |
| Northstar Asset Mgmt Group I | 1.8% | 9,913,654 | 128.2M USD | new | Q3 2016 1 quarter |
| Olin Corp | 1.8% | 6,181,302 | 126.8M USD | −42.4% reduced | Q3 2015 5 quarters |
| Vmware Inc | 1.7% | 1,603,889 | 117.6M USD | −28.8% reduced | Q1 2016 3 quarters |
| Atara Biotherapeutics Inc | 1.6% | 5,359,632 | 114.6M USD | unchanged | Q4 2014 8 quarters |
| Forward Pharma A/S | 1.6% | 5,367,300 | 112.7M USD | unchanged | Q4 2014 8 quarters |
| Liberty Interactive Corp | 1.4% | 2,469,533 | 98.5M USD | unchanged | Q2 2016 2 quarters |
| Colony Cap Inc | 1.2% | 4,445,936 | 81.0M USD | new | Q3 2016 1 quarter |
| Chipmos Tech Bermuda Ltd | 1.1% | 3,751,853 | 74.3M USD | unchanged | Q2 2013 or earlier 14 quarters |
| Northstar Rlty Fin Corp | 1.0% | 5,498,261 | 72.4M USD | new | Q3 2016 1 quarter |
| Klx Inc | 1.0% | 2,000,000 | 70.4M USD | unchanged | Q1 2015 7 quarters |
| Silver Run Acquisition Corp | 0.8% | 3,750,000 | 59.1M USD | unchanged | Q2 2016 2 quarters |
| American Intl Group Inc | 0.8% | 2,594,317 | 55.0M USD | +1.7% increased | Q2 2013 or earlier 14 quarters |
| Novagold Res Inc | 0.8% | 9,500,000 | 53.2M USD | unchanged | Q2 2013 or earlier 14 quarters |
| Liberty Media Corp Delaware | 0.7% | 2,994,010 | 52.0M USD | unchanged | Q2 2016 2 quarters |
| Office Depot Inc | 0.7% | 13,000,000 | 46.4M USD | new | Q3 2016 1 quarter |
| Cascadian Therapeutics Inc | 0.6% | 25,000,000 | 41.0M USD | unchanged | Q2 2016 2 quarters |
| Conyers Pk Acquisition | 0.5% | 3,712,500 | 37.1M USD | new | Q3 2016 1 quarter |
| Paratek Pharmaceuticals Inc | 0.4% | 2,044,498 | 26.6M USD | unchanged | Q4 2014 8 quarters |
| Saban Cap Acquisition Corp | 0.3% | 2,326,500 | 23.5M USD | new | Q3 2016 1 quarter |
| Credit Accep Corp Mich | 0.3% | 100,000 | 20.1M USD | unchanged | Q2 2016 2 quarters |
| RUN Sunrun | 0.3% | 2,848,082 | 17.9M USD | unchanged | Q3 2015 5 quarters |
| Kindred Biosciences Inc | 0.2% | 3,011,584 | 15.0M USD | −0.1% reduced | Q4 2013 12 quarters |
| Liberty Media Corp Delaware | 0.2% | 800,000 | 14.0M USD | unchanged | Q2 2016 2 quarters |
| Orexigen Therapeutics Inc | 0.1% | 2,226,839 | 7.4M USD | new | Q3 2016 1 quarter |
| Tobira Therapeutics Inc | < 0.1% | 160,829 | 6.4M USD | new | Q3 2016 1 quarter |
| Trilogy Metals Inc New | < 0.1% | 10,600,758 | 5.8M USD | new | Q3 2016 1 quarter |
| Citigroup Inc | < 0.1% | 102,553,207 | 5.4M USD | unchanged | Q2 2013 or earlier 14 quarters |
| Silver Run Acquisition Corp | < 0.1% | 950,000 | 5.3M USD | −24.0% reduced | Q2 2016 2 quarters |
| Conyers Pk Acquisition | < 0.1% | 1,237,500 | 1.4M USD | new | Q3 2016 1 quarter |
“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.
Plus 1 position in convertible bonds and bonds worth 40.5M USD as reported – not included in the weights.
Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.
- Theravance Inc principal 48.2M USD 40.5M USD
Breakdown by sector
- Financials 10.0%
- Technology 4.5%
- Industrials 0.3%
- not in our coverage 85.2%
Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.
How to read this page
- Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
- Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
- Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.
All superinvestor portfolios Screener: stocks held by superinvestors